R&D News | pharmaphorum

News

Sanofi, Orano cue up filings for GEP-NET radioligand therapy

Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.

News

After FDA exit, Peter Marks pops up at Lilly

The ousted former director of CBER, Peter Marks, has joined Eli Lilly as head of molecular discovery and infectious disease research.

News

MSD advances on a broad front with TL1A drug tulisokibart

MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.

News

AZ chalks up another positive trial for hypertension drug

AstraZeneca's baxdrostat has hit the mark in another phase 3 trial in resistant hypertension, keeping it on track for filing later this year.

News

Ignota's co-founder and chief executive, Sam Windsor

Ignota vacuums up Kronos Bio's drug programmes

Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

News

Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi

Regulatory T-cell scientist trio wins Nobel Prize

The Nobel Prize in Physiology or Medicine goes to three scientists for their work on regulatory T-cells, spawning hundreds of trials of new therapies.

Sanofi, Orano cue up filings for GEP-NET radioligand therapy

After FDA exit, Peter Marks pops up at Lilly

MSD advances on a broad front with TL1A drug tulisokibart

AZ chalks up another positive trial for hypertension drug

Ignota vacuums up Kronos Bio's drug programmes

Regulatory T-cell scientist trio wins Nobel Prize

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks